🔗 Share this article

While America undertakes historic revisions to its immunization recommendations, an unexpected name appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccines during the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Health officials were set to unveil radical changes to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US out of alignment with many the international standard with insufficient data for public health gain. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

A Shift at the FDA

The acting appointment could signify a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US to become more like Denmark's approach, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has little discernible experience in medication creation, regulation or leadership, which has been typical for former leaders of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “understand regulatory frameworks and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led the center have had.”

CDER has an immense workload at the FDA, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be looked after,” Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a major management aspect to the job, which supervises more than 5,000 personnel. “It’s a huge management job, if you do it right,” she added.

Official Statement and Controversial Policies

When asked about inquiries about Høeg’s fitness for the role and whether this selection signifies increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “inquiries are based on inaccurate presumptions”.

“This background aligns with the responsibilities of her role,” the official said, citing the time Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a disputed expedited medication authorization process that apparently troubled her former heads. “How are these therapies being selected for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Public Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, past, some experts said. She authored a study using unverified crowd-sourced reports to determine the frequency of myocarditis following COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the new administration encompassed changing guidelines for new vaccines and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has reportedly floated the idea of barring young men from obtaining Covid vaccinations.

“She’s an all-around dogmatist who starts off with her beliefs and works backwards to accommodate the evidence in a very deceptive, fraudulent way,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|